BTC Capital Management Inc. Sells 4,196 Shares of Amgen Inc. $AMGN

BTC Capital Management Inc. trimmed its position in shares of Amgen Inc. (NASDAQ:AMGN) by 38.1% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 6,812 shares of the medical research company’s stock after selling 4,196 shares during the quarter. BTC Capital Management Inc.’s holdings in Amgen were worth $2,228,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the company. Vanguard Group Inc. boosted its position in shares of Amgen by 0.3% during the third quarter. Vanguard Group Inc. now owns 53,876,851 shares of the medical research company’s stock valued at $15,204,047,000 after purchasing an additional 165,281 shares in the last quarter. State Street Corp lifted its position in Amgen by 0.6% during the second quarter. State Street Corp now owns 29,357,026 shares of the medical research company’s stock valued at $8,196,775,000 after buying an additional 177,035 shares during the period. Capital International Investors boosted its holdings in shares of Amgen by 1.5% during the 3rd quarter. Capital International Investors now owns 19,192,995 shares of the medical research company’s stock valued at $5,414,296,000 after buying an additional 282,219 shares in the last quarter. Capital World Investors boosted its holdings in shares of Amgen by 11.5% during the 3rd quarter. Capital World Investors now owns 18,795,474 shares of the medical research company’s stock valued at $5,303,578,000 after buying an additional 1,935,876 shares in the last quarter. Finally, Capital Research Global Investors grew its position in shares of Amgen by 2.7% in the 3rd quarter. Capital Research Global Investors now owns 4,731,290 shares of the medical research company’s stock worth $1,335,168,000 after buying an additional 122,631 shares during the period. 76.50% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on AMGN shares. Mizuho lifted their price target on shares of Amgen from $280.00 to $295.00 and gave the company an “outperform” rating in a research report on Tuesday, February 10th. BMO Capital Markets raised their target price on shares of Amgen from $335.00 to $372.00 and gave the company an “outperform” rating in a research note on Wednesday, December 3rd. Oppenheimer set a $400.00 target price on shares of Amgen and gave the company an “outperform” rating in a report on Thursday, January 29th. Rothschild & Co Redburn boosted their price target on Amgen from $180.00 to $200.00 and gave the stock a “sell” rating in a research report on Wednesday, February 18th. Finally, Truist Financial upped their price target on Amgen from $318.00 to $319.00 and gave the stock a “hold” rating in a research note on Thursday, January 8th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $354.60.

Amgen Stock Up 0.8%

NASDAQ:AMGN opened at $351.85 on Wednesday. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. The firm has a market cap of $189.67 billion, a P/E ratio of 24.73, a P/E/G ratio of 3.46 and a beta of 0.45. Amgen Inc. has a fifty-two week low of $261.43 and a fifty-two week high of $391.29. The firm has a 50-day simple moving average of $363.37 and a two-hundred day simple moving average of $331.58.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.76 by $0.53. The firm had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The business’s revenue was up 8.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Analysts predict that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be paid a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 2.9%. The ex-dividend date is Friday, May 15th. Amgen’s dividend payout ratio (DPR) is currently 70.84%.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Positive cardiovascular data for Amgen’s Repatha: a trial showed a 31% reduction in first major cardiovascular events in a high‑risk population without known significant atherosclerosis — a tailwind for Repatha’s commercial outlook and long‑term revenue potential. Amgen: Repatha Cuts Risk…
• Positive Sentiment: High‑profile media/analyst praise has supported sentiment — Jim Cramer noted Amgen as an attractive large‑cap biotech holding, and Zacks highlighted Amgen’s resilient drug portfolio as offsetting industry headwinds. Those endorsements can boost short‑term demand. Amgen (AMGN) Stock Up Since Jim Cramer Said…
• Positive Sentiment: Zacks analyst commentary reiterates AMGN’s upside from a diversified drug portfolio and steady cash flows, supporting the stock amid sector volatility. The Zacks Analyst Blog Roche Holding, AT&T and Amgen
• Neutral Sentiment: Sector news (other biotech trial readouts and IPO activity) is driving broader health‑care flows but is not specific to Amgen’s fundamentals; watch market‑wide risk appetite. Viridian tumbles on positive data for key eye drug prospect
• Negative Sentiment: FDA safety warning on Tavneos (Amgen’s drug for certain rare autoimmune diseases): regulators identified dozens of drug‑induced liver injury cases (reports cite ~76 cases) and urged close monitoring and prompt discontinuation if liver damage is suspected — a material safety/regulatory overhang that could affect prescribing, labeling, and long‑term sales. US FDA warns of liver injury cases tied to Amgen’s rare disease drug
• Negative Sentiment: Competitive pressure: Teva’s FDA approval of a Prolia (denosumab) biosimilar and other biosimilar filings increase competition in bone‑health markets, which could weigh on Amgen’s Prolia pricing and market share over time. TEVA’s Prolia Biosimilar Gets FDA Nod, Xolair Filing Accepted

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.